This is a working overview of insulin-like growth factor 1, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-29 and is reviewed periodically as new material appears.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility | Soluble in water | Consistent with peptide nature |
| Typical storage | 2 to 8 degrees Celsius | Refrigerated, dry, protected from light |
| Common analytical method | Reversed-phase HPLC | Purity and impurity profiling |
| Identity confirmation | Mass spectrometry | Molecular mass verification |
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
In contrast to organomagnesium compounds, organocalcium compounds are not similarly useful, with one major exception, calcium carbide, CaC2. This material, which has historic significance, is prepared by heating calcium oxide with carbon. According to X-ray crystallography, calcium carbide can be described as Ca2+ derivative of acetylide, C22-, although it is not a salt. Several million tons of calcium carbide are produced annually. Hydrolysis gives acetylene, which is used in welding and a chemical precursor. Reaction with nitrogen gas converts calcium carbide to calcium cyanamide. A dominant theme in molecular organocalcium chemistry is the large radius of calcium, which often leads to high coordination numbers. For example, dimethylcalcium appears to be a 3-dimensional polymer, whereas dimethylmagnesium is a linear polymer with tetrahedral Mg centers. Bulky ligands are often required to disfavor polymeric species. For example, calcium dicyclopentadienyl, Ca(C5H5)2 has a polymeric structure and thus is nonvolatile and insoluble in solvents. Replacing the C5H5 ligand with the bulkier C5(CH3)5 (pentamethylcyclopentadienyl) gives a soluble complex that sublimes and forms well-defined adducts with ethers. Organocalcium compounds tend to be more similar to organoytterbium compounds due to the similar ionic radii of Yb2+ (102 pm) and Ca2+ (100 pm). Organocalcium compounds have been well investigated. Some such complexes exhibit catalytic properties, although none have been commercialized.
Vildagliptin, sold under the brand name Galvus among others, is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. Bold textIt was approved by the European Medicines Agency (EMA) in 2007. The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral treatment for type-2 diabetes. Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.
=== C-terminal modifications === The C-terminus of proteins can be modified posttranslationally, most commonly by the addition of a lipid anchor to the C-terminus that allows the protein to be inserted into a membrane without having a transmembrane domain.
Paul, Minnesota: Motorbooks International Publishers, 1995. ISBN 0-7603-0002-X. Ethell, Jeffrey L. Mustang: A Documentary History of the P-51. London: Jane's Publishing, 1981. ISBN 0-531-03736-3 Ethell, Jeffrey L. P-51 Mustang: In Color, Photos from World War II and Korea. St. Paul, Minnesota: Motorbooks International Publishers & Wholesalers, 1993. ISBN 0-87938-818-8. Ethell, Jeffrey and Robert Sand. World War II Fighters. Minneapolis, Minnesota: Zenith Imprint, 2002. ISBN 978-0-7603-1354-1. Forsyth, Robert. JV44: The Galland Circus. Burgess Hill, West Sussex, UK: Classic Publications, 1996. ISBN 0-9526867-0-8 Furse, Anthony. Wilfrid Freeman: The Genius Behind Allied Survival and Air Supremacy, 1939 to 1945. Staplehurst, UK: Spellmount, 1999. ISBN 1-86227-079-1. Gilman J.D. and J. Clive. KG 200. London: Pan Books Ltd., 1978. ISBN 0-85177-819-4. Glancey, Jonathan (2006), Spitfire: The Illustrated Biography, London: Atlantic Books, ISBN 978-1-84354-528-6 Gordon, Doug (July–August 2001). "Tac Recon Masters: The 66th Tactical Reconnaissance Wing in Europe, Part One". Air Enthusiast (94): 31–39. ISSN 0143-5450. Gordon, Yefim. Soviet Air Power in World War 2. Hinckley, UK: Midland Ian Allan Publishing, 2008. ISBN 978-1-85780-304-4. Grant, William Newby. P-51 Mustang. London: Bison Books, 1980. ISBN 0-89009-320-2. Green, William and Gordon Swanborough. The Great Book of Fighters. St. Paul, Minnesota: MBI Publishing, 2001. ISBN 0-7603-1194-3. Gruenhagen, Robert W. Mustang: The Story of the P-51 Fighter (rev. ed.). New York: Arco Publishing Company, Inc., 1980. ISBN 0-668-04884-0.
Sources: en.wikipedia.org
==== Testosterone replacement therapy (TRT) and secondary polycythemia ==== Testosterone replacement therapy (TRT) causes secondary polycythemia by stimulating the body's natural pathways that regulate red blood cell production, rather than from an inherent bone marrow disorder. Testosterone increases the production of erythropoietin (EPO) in the kidneys, a hormone that signals the bone marrow to make more red blood cells. At the same time, testosterone suppresses the liver hormone hepcidin, which normally limits the absorption and mobilization of iron. With less hepcidin, iron becomes more available for hemoglobin synthesis, further fueling red blood cell production. This combination of increased EPO signaling and enhanced iron supply amplifies erythropoiesis, leading to elevated hematocrit and hemoglobin levels. The effect is most pronounced with injectable forms of testosterone that create high peak serum levels, which strongly stimulate these pathways. Because the mechanism is driven by a hormonal stimulus and not by a primary bone marrow abnormality, the condition is classified as secondary polycythemia. Clinically, this distinction is important, as TRT-induced secondary polycythemia resolves or improves with dose adjustment, delivery method changes, or therapeutic phlebotomy, whereas primary polycythemia reflects a chronic clonal disorder of hematopoietic stem cells.
=== Use of DNA mismatch-binding proteins === DNA mismatch-binding proteins can distinguish single nucleotide mismatches and thus facilitate differential analysis of SNPs. For example, MutS protein from Thermus aquaticus binds different single nucleotide mismatches with different affinities and can be used in capillary electrophoresis to differentiate all six sets of mismatches.
Amino acids, including tryptophan, are used as building blocks in protein biosynthesis, and proteins are required to sustain life. Tryptophan is among the less common amino acids found in proteins, but it plays important structural or functional roles whenever it occurs. For instance, tryptophan and tyrosine residues play special roles in "anchoring" membrane proteins within the cell membrane. Tryptophan, along with other aromatic amino acids, is also important in glycan-protein interactions. In addition, tryptophan functions as a biochemical precursor for the following compounds:
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.
Reversed-phase high-performance liquid chromatography is commonly used to separate and quantify the peptide and its impurities. Mass spectrometry is often paired with it to confirm identity. Together they provide a profile of related substances.
Extreme pH values accelerate hydrolytic degradation of the peptide backbone. Buffered solutions in a near-neutral range generally slow this process. Solution age and temperature also affect the rate of breakdown.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.